8-K: Vivos Therapeutics Stockholders Re-Elect Board, Approve Equity Plan

Vivos Therapeutics, Inc. announced the successful re-election of its board of directors, approval of an equity incentive plan amendment, and ratification of its independent auditor at its 2025 Annual Meeting.

Summary

• Vivos Therapeutics, Inc. held its 2025 annual meeting of stockholders on November 4, 2025.
• 7,504,807 shares of common stock were entitled to vote as of the September 8, 2025 record date.
• A quorum was present with approximately 4,968,728 shares of voting stock represented.
• Stockholders re-elected R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, and Dr. Matthew Thompson to the Board of Directors for a one-year term expiring at the 2026 Annual Meeting.
• An amendment to the company's 2024 Omnibus Equity Incentive Plan was approved and adopted with 2,453,436 shares voted for, 516,368 against, 2,275 abstaining, and 1,996,649 broker non-votes.
• The appointment of Baker Tilly US, LLP, successor to Moss Adams LLP, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 4,861,139 shares voted for, 102,827 against, and 4,762 abstaining.

Sentiment

Score: 7

Explanation: The successful passage of all proposals at the annual meeting, including the re-election of the board and approval of the equity plan, indicates stable corporate governance and shareholder support for current management and incentive structures. While there was some dissent on the equity plan, it passed comfortably.

Positives

• Successful re-election of all six director nominees ensures continuity in leadership.
• Approval of the 2024 Omnibus Equity Incentive Plan amendment provides management with tools for employee motivation and retention.
• Ratification of the independent auditor, Baker Tilly US, LLP, ensures compliance with financial reporting requirements.

Negatives

• A significant number of broker non-votes (1,996,649) for the director elections and equity plan amendment indicates a portion of shares were not voted on these discretionary matters.
• 516,368 shares were voted against the amendment to the 2024 Omnibus Equity Incentive Plan, suggesting some shareholder dissent regarding the plan.

Future Outlook

The re-elected directors will serve until the 2026 Annual Meeting of Stockholders, providing continuity for the company's strategic direction. The approved amendment to the 2024 Omnibus Equity Incentive Plan will be implemented to support employee motivation and retention.

Industry Context

This filing is a standard corporate governance update, reflecting routine annual meeting procedures common across publicly traded companies. The approval of an equity incentive plan is a typical mechanism for attracting and retaining talent in competitive industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Affirmation of current board and corporate governance structure. Potential for increased value through motivated employees, balanced against potential dilution from the equity incentive plan.
• Employees/Management: The approved equity incentive plan provides a mechanism for compensation and motivation, potentially improving retention and performance.

Next Steps

• The re-elected directors will continue to serve on the Board until the 2026 Annual Meeting of Stockholders.
• The amended 2024 Omnibus Equity Incentive Plan will be implemented.
• Baker Tilly US, LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

This 8-K filing primarily details routine corporate governance matters, specifically the outcomes of the annual stockholders' meeting. The re-election of directors and approval of the equity plan are expected procedural events that do not inherently signal a significant change in the company's operational or financial trajectory. There is no new financial data, strategic shifts, or material events disclosed that would warrant a change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate as investors should await more substantive operational or financial updates.

Keywords

Vivos Therapeutics, VVOS, SEC filing, 8-K, Annual Meeting, Stockholders, Board of Directors, Director Election, Equity Incentive Plan, Auditor Ratification, Corporate Governance, NASDAQ